Introduction
Leishmania species are distributed worldwide. During its life cycle, the parasite goes through two developmental stages. The promastigote form of the parasite resides in the intestinal tract of the insect vector. The amastigote form of the parasite resides in macrophages and other mononuclear phagocytes in the mammalian host. The pentavalent antimonial drugs Pentostam and Glucantime are the first-line treatment for leishmaniasis, and resistance to those drugs is a serious clinical problem (2, 3) . To create the active form of the drug, Sb(V) is first reduced to Sb(III) (4) . Reduction occurs preferentially in the amastigotes, which are more sensitive to Pentostam than are promastigotes (5, 6) . Arsenic and antimony have similar properties and are transported by the same channels (7, 8) , carriers (9, 10) and pumps (11, 12) . We propose that at least a portion of the Sb(V) in Pentostam is reduced by a leishmanial As(V) reductase. Arsenate reductases are ubiquitous in prokaryotes and archaea and are essential for conferring resistance to arsenate (13) . In these organisms arsenate reductase enzymes apparently arose independently at least twice. Recently a L. donovani enzyme related to glutathione S-transferases has been shown to catalyze GSH-dependent reduction of arsenate and antimonate in vitro (14) . While this protein is a reasonable candidate for a Pentostam reducing enzyme, there are no data that directly demonstrate a relationship of this enzyme and drug sensitivity in Leishmania amastigotes.
In contrast, the ScAcr2p arsenate reductase from Saccharomyces cerevisiae reduces arsenate to arsenite both in vivo and in vitro (15) (16) (17) (18) . ScAcr2p is homologous to the Cdc25a cell cycle protein tyrosine phosphatase (19) and to rhodanese, a thiosulfate sulfurtransferase (20) . ScAcr2p uses GSH and glutaredoxin as cofactors (17) . Because of its relatedness to protein phosphatases, it is difficult to identify paralogous eukaryotic proteins solely by homology searches of DNA databases. We used the ScAcr2p sequence to identify a closely related Leishmania major sequence. This open reading frame, designated LmACR2, was cloned into both yeast and E. coli expression vectors. LmACR2 functionally complements the arsenate sensitive phenotypes of the ScACR2 deletion of S. cerevisiae and an deletion of the Escherichia coli arsC gene, which encodes a bacterial arsenate reductase. LmACR2 was purified and characterized. The Leishmania enzyme requires GSH and glutaredoxin for arsenate reductase activity, with a Km of 6 mM for As(V) and is inhibited by As(III), Sb(III) and phenylarsine oxide. LmACR2 also reduces Sb(V) to Sb(III) with a Km of 7 µM. To demonstrate a relationship between LmACR2 and Pentostam activity, LmACR2 was transfected into L. infantum promastigotes. Macrophage-infected amastigotes derived from these transfected cells exhibited increased sensitivity to Pentostam. This is the first demonstration of an enzyme that is involved in and probably required for action of the drug Pentostam in intracellular Leishmania amastigotes.
Experimental procedures
Reagents. All reagents were from Sigma-Aldrich. As(V), Sb(V), As(III) and Sb (III) were purchased in the form of sodium arsenate, potassium hexahydroxy antimonate, sodium arsenite and potassium antimonyl tartrate, respectively. DNA manipulation reagents were obtained from Qiagen and Invitrogen.
Cloning of LmACR2. The Leishmania Genome Network GeneDB was inspected for a L. major homologue of ScACR2. The closest to ScACR2 (Systematic Name:
LmjF32.2740) is 384 bp in length and localized in chromosome 32. The full-length gene, designated LmACR2, was cloned by polymerase chain reaction (PCR) using Metalloid sensitivity assays. Cells of E. coli were grown in a low phosphate medium (21) at 37 o C supplemented with 50 to 125 µg/ml ampicillin, as appropriate. The arsente resistance phenotype of cells expressing ACR2 was determined in E. coli strains W3110 (wild type) or WC3110 (∆arsC), as described previously (17) .
Overnight cultures were diluted 100-fold in low phosphate medium containing various concentrations of sodium arsenate and 0.2% arabinose. Growth was estimated from the absorption at 600 nm after 15 h of growth at 37 o C.
In Saccharomyces cerevisiae W303-1B and RM1 (15) Assay of arsenate reductase activity. Arsenate reductase activity was assayed at 37 °C using a coupled assay (17) . The assay buffer contained 50 mM MOPS, 50 mM MES, pH 6.5, 0.1 mg/ml bovine serum albumin, 0.25 mM NADPH, 5 nM yeast glutathione reductase (Calbiochem), 1 mM GSH, and 50-100 µM LmACR2.
Reduction of 2-hydroxyethyldisulfide was used to ensure that the rate of the coupling system was not rate limiting in the presence of inhibitors. Sodium arsenate, glutaredoxins and inhibitors were added as indicated. Reductase activity was monitored at 340 nm and expressed as nmol NADPH oxidized per mg of LmACR2 sequence identity and 44% similarity (Fig.1) .
Expression of LmACR2 functionally complements the arsenate sensitive phenotype of an arsenate reductase deletion of E. coli. LmACR2 was cloned behiind the arabinose promoter in plasmid pBAD-Myc-HisA with a C-terminal six-histidine tag.
ACR2 genes from either S. cerevisiae (ScACR2) or L. major (LmACR2) with six histidine codons at the 3' end of the genes restored arsenate resistance in the E. coli arsC deletion strain WC3110 (17) (Fig. 2) . LmACR2 complemented better than ScACR2, perhaps because of improved solubility. There was no complementation with Purification of LmACR2. When expressed in E. coli, LmACR2 is a soluble cytosolic protein that was purified by NiNTA chromatography. The molecular mass of purified LmACR2 was determined by gel filtration chromatography using a Sephacryl S-100 column (Fig. 3) . From the nucleotide sequence of the LmACR2 gene with the Cterminal myc-epitope and six histidine tag, the gene product has a predicted mass 17,454 Da. From gel filtration, a mass of approximately 17 kDa was determined, consistent with a monomer. In contrast, yeast ScAcr2p elutes as a homodimer (17) LmACR2 is an arsenate reductase. The ability of LmACR2 to reduce arsenate to arsenite was examined using a coupled assay developed for ArsC and ScAcr2p (17, 28) . Reduction of arsenate was catalyzed by LmACR2 in the presence of Grx2, the most effective E. coli glutaredoxin for ArsC (25) (Fig. 4) . Both yeast ScGrx1p and the E. coli Grx2 could serve as electron donor for LmACR2 activity ( (Fig. 7B) . By comparison, the K m for Sb(V) is 1000-fold lower than for As(V), and the V max is three-fold higher. These results clearly demonstrate that LmACR2 is a metalloid reductase with much higher affinity for Sb(V) than As(V).
Expression of LmACR2 confers Pentostam sensitivity in Leishmania. If LmACR2 is
responsible for the physiological effect of Pentostam, then the reduction of Sb(V) to Sb(III) by LmACR2 should be related to sensitivity of the parasite to Pentostam. The effect of expression of LmACR2 in intracellular amastigotes was examined (Fig. 8) .
LmACR2 in plasmid pSP-ACR2HYG was transfected into L. infantum promastigotes, which were used to infect macrophages. These parasites express luciferase to facilititate measurement of drug susceptibility (22) . Susceptiblity to Pentostam was determined in these intracellular (macrophage infected) amastigotes (Fig. 8) .
Because this is a wild type strain diploid for LmACR2, reductase activity is expressed endogenously. Even so, there is an unambiguous increase in sensitivity to Pentostam in intracellular amastigotes expressing LmACR2 in trans compared to vectortransfected cells. We expect that the effect of LmACR2 expression would be much more dramatic in an ACR2 knockout. This is the first demonstration of an enzyme that is involved in and probably required for action of the drug Pentostam in intracellular amastigotes of Leishmania.
Discussion
Treatment of leishmaniasis is limited by the availability of effective drugs (29) .
Pentostam and Glucantime are the most widely used drugs. Inorganic pentavalent antimony is rather insoluble, which limits its utility as a drug.
Pentostam and
Glucantime are noncovalent chelates of Sb(V) with improved solubility and uptake properties than free Sb(V) and lower toxicity than Sb(III). In spite of their greater solubility, they must still be administered parenterally, which is a serious limitation in their use for the treatment of leishmaniasis. In the human host, the parasite exists in the intracellular amastigote form inside of macrophages.
It is generally accepted that the Sb(V) in these drugs must be reduced to Sb(III) to create the active form of the drug, but does reduction occur in the macrophage, in the amastigote or both? On the one hand, axenic amastigotes of L.
infantum produced in vitro have been reported to be more resistant to Pentostam than intracellular amastigotes grown in macrophages, leading to the suggestion that macrophages reduce Pentostam to Sb(III), which is then taken up by the intracellular amastigotes (4). As(III) is taken into most cells by aquaglyceroporins (7, 8) , and several Leishamia species have an aquaglyceroporin, AQP1, that we have shown catalyzes Sb(III) uptake (30) . Yet axenic amastigotes of L. donovani have been reported to reduce Sb(V), and a Pentostam resistant mutant had lower reduction (6).
These considerations suggest that Sb(V) is reduced to Sb(III) in both the human host and the parasite (Fig. 9) . While axenic amastigotes reduce Pentostam (6), no protein has been associated with this activity. In this study we identified a L.
major homologue of known arsenate resistance enzymes and showed that it is an Sb(V) reductase. Its properties are similar to those of the yeast enzyme but exhibit some differences. For one thing, the V max of purified LmACR2 is considerably less than that of ScAcr2p, which is in the range of 300 nmol/mg/min. The low specific activity of purified LmACR2 may be due in part to the fact that trypanosomes and Leishmania do not utilize the wide-spread system of GSH and GSH reductase. In trypanosomatidae, these are replaced by N 1 ,N 8 -bis(glutathionyl)spermidine (trypanothione), and trypanothione reductase (31) (32) (33) (34) . Replacing glutaredoxin is tryparedoxin (34, 35) . Thus, it is reasonable to assume that a leishmanial homologue of an arsenate reductase would function more efficiently with trypanothione, trypanothione reductase and tryparedoxin, which were not available for this study. A second apparent difference between the parasite and yeast enzymes is that LmACR2 is a monomer while ScAcr2p is a homodimer. LmACR2 also exhibits hyperbolic kinetics ( Third, in preliminary experiments we have found the transfection of a field isolate from India with LmACR2 made the intracellular amastigotes sensitive to 300 µg/ml of pentostam, whereas the same field isolate without the transfected gene was completely resistant to that level of drug (data not shown). These results are consistent with involvement of LmACR2 in conversion of the drug to its active form.
Expression of LmACR2 may be a predictor of success of Sb(V) treatment.
Conversely, mutations in LmACR2 may be an unrecognized cause of drug failure. 
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